Amylyx Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Welcome to the Morgan Stanley Global Healthcare Conference. I'm [Jeff Hung], one of the biotech analysts. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
For this session, we have Amylyx Pharmaceuticals with co-CEOs, Justin Klee and Joshua Cohen. Welcome.
Thanks so much for having us.
Questions & Answers
So for those who may not be as familiar with Amylyx, can you provide a brief introduction?
Yes, happy to. So thanks so much for having us. Justin, Josh, we're the co-CEOs, co-founders at Amylyx. So Amylyx was founded about 10.5 years ago. We are focused in neurodegenerative diseases and particularly ALS. The company is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |